Information Provided By: 
Fly News Breaks for October 24, 2016
CEMP
Oct 24, 2016 | 08:06 EDT
Jefferies analyst Eun Yang believes sentiment is negative on Cempra's Solithera for the treatment of community-acquired bacterial pneumonia ahead of the FDA panel on November 4. The analyst thinks liver safety concerns are likely overblown and sees a 70%-80% likelihood of a positive panel outcome. The risk/reward skews to the upside with greater than 50% appreciation potential, Yang tells investors in a research note. She keeps a Buy rating on Cempra with a $40 price target.
News For CEMP From the Last 2 Days
There are no results for your query CEMP
